Compare AbCellera Biologics Inc (ABCL) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dicks Sporting Goods Inc — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Dicks Sporting Goods Inc trades at $215.9 (market cap $19.97B). The key difference: Dicks Sporting Goods Inc is far larger — about 8.5× AbCellera Biologics Inc's market cap, and Dicks Sporting Goods Inc pays a 2.24% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DKS | |
|---|---|---|
Market Cap | $2.35B | $19.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $239.17 |
52-Week Low | $2.78 | $187.78 |
Enterprise Value | $1.99B | $26.76B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Dick's Sporting Goods (DKS) trades at $229.02, down 3.03% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with consistent earnings beats, a P/E of 22.3, and a net income margin of 4.71%. Recent developments include the launch of ScoreCard+ loyalty program and partnerships with Lids, enhancing growth prospects amid positive analyst sentiment.
The outlook for DKS is positive, supported by robust earnings performance and strategic initiatives. Risks include potential fiduciary concerns highlighted in recent legal investigations and competitive pressures. With a consensus price target of $261, representing a 14% upside, the stock presents a compelling opportunity, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
